Key result
Tenecteplase is a new fibrinolytic agent used to treat ST-segment elevation acute myocardial infarction that offers advantages over other fibrinolytic agents.
This article provides a review of tenecteplase, a fibrinolytic agent for ST-segment elevation acute MI, including its actions, indications, contraindications, and use.
Answers are grounded in this paper and cite their sources.
Tenecteplase may warrant consideration for STEMI fibrinolysis; leaves open need for updated head-to-head trials.
Acute coronary syndrome can mean anything from unstable angina to acute myocardial infarction (MI) with ST-segment elevation. Tenecteplase, a new fibrinolytic agent used to treat ST-segment elevation acute MI, has some advantages over other fibrinolytic agents. This article describes tenecteplase's actions, indications, contraindications, and use.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2001) studied this question. Tenecteplase is a new fibrinolytic agent used to treat ST-segment elevation acute myocardial infarction that offers advantages over other fibrinolytic agents.
Synapse has enriched 10 related papers. Consider them for comparative context: